BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  ITM Presents Positive Topline Phase 3 COMPETE Trial Data with n.c.a. 177Lu-edotreotide (ITM-11), a Targeted Radiopharmaceutical Therapy, in Patients with Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors at the ENETS 2025 Conference

  March 6, 2025

   · 

  8 min read
• Press Releases

  Orbital Therapeutics Appoints Geno Germano, Biopharma Veteran, to its Board of Directors

  March 6, 2025

   · 

  2 min read
• Press Releases

  Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

  A growing body of clinical evidence supports the use of Firefly’s FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia

  March 6, 2025

   · 

  10 min read
• Press Releases

  Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine

  March 6, 2025

   · 

  8 min read
• Press Releases

  Kamada Declares Special Cash Dividend of $0.20 Per Share

  March 6, 2025

   · 

  6 min read
• Press Releases

  NETRAMARK UNVEILS AI DRIVEN INSIGHTS FOR MAJOR DEPRESSIVE DISORDER AND SCHIZOPHRENIA AT ISCTM CONFERENCE

  March 6, 2025

   · 

  7 min read
• Press Releases

  Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

  March 6, 2025

   · 

  13 min read
• Press Releases

  Solid Biosciences to Participate at Upcoming March 2025 Investor Conferences

  March 6, 2025

   · 

  2 min read
• Press Releases

  Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

  The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent

  March 6, 2025

   · 

  6 min read
• Press Releases

  Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

  March 6, 2025

   · 

  16 min read